Yang Wang, MD
Hematology & Oncology · Albuquerque, NMNPI 1073810966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 9.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,451, 2.8 times the $525 reported in 2019.
Across 162 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$303
- Novartis$283
- Daiichi Sankyo Inc.$225
- Takeda Pharmaceuticals U.S.A., Inc.$204
- E.r. Squibb & Sons, L.L.C.$151
- Gilead$138
- plus $2K from 39 others
Across 2 payments — averaging $76,529 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GE HealthCare$153K
What the payments were for
- Food & beverage$3,04495%
- Education$1595%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,203 in reported general payments places this provider in the 55th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 58 | $726,689 |
| BrukinsaZanubrutinib | 47 | $589,243 |
| RevlimidLenalidomide | 31 | $515,196 |
| CalquenceAcalabrutinib Maleate | 30 | $472,213 |
| ImbruvicaIbrutinib | 26 | $422,748 |
| TagrissoOsimertinib Mesylate | 22 | $373,281 |
| KisqaliRibociclib Succinate | 21 | $326,677 |
| JakafiRuxolitinib Phosphate | 18 | $323,257 |
| XtandiEnzalutamide | 21 | $284,686 |
| NinlaroIxazomib Citrate | 17 | $214,322 |
| Abiraterone Acetate | 82 | $185,736 |
| ErleadaApalutamide | 12 | $172,182 |
| VenclextaVenetoclax | 27 | $66,291 |
| XareltoRivaroxaban | 54 | $59,037 |
| Imatinib Mesylate | 13 | $42,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $111 | $845,49452 claims |
| Beigene USA, Inc.Brukinsa | $33 | $589,24347 claims |
| Bristol Myers SquibbRevlimid | $30 | $515,19631 claims |
| NovartisKisqali | $283 | $326,67721 claims |
| Incyte CorporationJakafi | $25 | $323,25718 claims |
| Astellas Pharma US IncXtandi | $46 | $284,68621 claims |
| Johnson & JohnsonErleada, Xarelto | $303 | $231,21966 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $204 | $214,32217 claims |
| AbbVieVenclexta, Creon | $40 | $98,73141 claims |
| PfizerEliquis | $46 | $28,13743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Albuquerque
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Scott HerbertAlbuquerque$14K
- Jose AvitiaAlbuquerque$11K
- Zoneddy DayaoAlbuquerque$10K
- Toufic TannousAlbuquerque$10K
- Amy TarnowerAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.